سعر ساندوستاتين 0.1مجم/مل 5 امبولات 2023

Octreotide 0.1 mg/ml (100 mcg/ml) solution for subcutaneous injection (Sandostatin, Novartis); pack of 5 ampoules.

• Acromegaly: to reduce GH and IGF-1 in patients with inadequate response to, or who cannot be treated with, surgery, pituitary irradiation and bromocriptine.DailyMed (U.S. National Library of Medicine)
• Symptomatic treatment of severe diarrhoea and flushing in metastatic carcinoid tumours.DailyMed (U.S. National Library of Medicine)
• Profuse watery diarrhoea associated with VIP-secreting tumours (VIPomas).DailyMed (U.S. National Library of Medicine)

• Most common (>10%) in acromegaly: gallbladder abnormalities, sinus bradycardia, diarrhoea, loose stools, nausea, abdominal discomfort, hyperglycaemia, hypothyroidism; in other patients: gallbladder abnormalities.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Sensitivity to octreotide or any of its components.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cholelithiasis and its complications (monitor periodically, stop if complications suspected); hypo- or hyperglycaemia (monitor glucose, adjust antidiabetic therapy); hypothyroidism (monitor thyroid function); bradycardia, arrhythmias and conduction abnormalities; steatorrhoea and fat malabsorption; reduced vitamin B12 levels.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CiclosporinOctreotide may decrease ciclosporin blood levels and result in transplant rejection.DailyMed (U.S. National Library of Medicine)
• Insulin and oral hypoglycaemic agentsOctreotide inhibits insulin and glucagon secretion; monitor blood glucose and adjust antidiabetic therapy.DailyMed (U.S. National Library of Medicine)
• Beta-blockers and other bradycardia-inducing drugsPossible additive reduction in heart rate; dose adjustment may be needed.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform a drug-associated risk; no adverse developmental effects in rats and rabbits at 7–13 times the MRHD; transient growth retardation in rat offspring.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed infant; octreotide passes into rat milk at low concentration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Octreotide (as acetate): Cyclic octapeptide somatostatin analogue that inhibits secretion of growth hormone, glucagon, insulin, serotonin, gastrin, VIP and other gastroenteropancreatic peptides.